Skip to main content

Advertisement

SpringerLink
Log in

Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Objective

To determine whether the specific genotype of exon 19 deletion has a better survival outcome than that of exon 21 substitution in advanced lung adenocarcinoma with EGFR mutant patients that were treated with EGFR-TKIs as second-line therapy after first-line chemotherapy.

Methods

Between April 1, 2010 and December 31, 2012, the detailed clinical information of 128 patients was screened from the hospital information database of the First Affiliated Hospital and the Third Affiliated Hospital of Kunming Medical University by inclusion/exclusion criteria. Then, a telephone follow-up and a review of all patients’ image data were done to obtain the survival information of all patients. After that, all patients’ data were processed by IBM® SPSS® version 19.0.

Results

There were correlations between EGFR mutation status, gross tumor type and PFS or OS according to the Kaplan–Meier survival analyses and log-rank tests. The exon 19 deletions had significantly better survival outcomes in comparison to exon 21 substitutions (median PFS: 8.1 vs. 6.8 months, P = 0.002; median OS: 17.6 vs. 12.5 months, P = 0.000). Stratification analyses of PFS and OS revealed that exon 19 deletions had a survival superior to exon 21 substitutions.

Conclusion

Compared with L858R mutation, the genotype of exon 19 deletion had a better survival outcome in terms of PFS and OS in patients with advanced lung adenocarcinoma treated with EGFR-TKIs as second-line therapy after first-line chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics. Ca Cancer J Clin. 2014;64:9–29.

    Article  PubMed  Google Scholar 

  2. National health and family planning commission of the People’s Republic of China. China Health Statistics Annual, 2013. http://www.nhfpc.gov.cn/htmlfiles/zwgkzt/ptjnj/year2013/index2013.html.

  3. Baas P, Bolderbos JSA, Heuvel MV. Chemoradiation therapy in non-small cell lung cancer. Curr Opin Oncol. 2011;23(2):140–9.

    Article  CAS  PubMed  Google Scholar 

  4. Favaretto AG, Pasello G, Magro C. Second and third line treatment in advanced non-small cell lung cancer. Discov Med. 2009;8:204–9.

    PubMed  Google Scholar 

  5. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589–97.

    Article  CAS  PubMed  Google Scholar 

  6. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–103.

    CAS  PubMed  Google Scholar 

  7. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: the TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354–62.

    CAS  PubMed  Google Scholar 

  8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;3:123–32.

    Article  Google Scholar 

  9. Perng RP, Yang CH, Chen YM, Chang GC, Lin MC, Hsieh RK, et al. High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer. 2008;62:78–84.

    Article  PubMed  Google Scholar 

  10. Kawaguchi Tomoya, Ando Masahiko, Asami Kazuhiro, Okano Y, Fukuda M, Nakagawa H, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol. 2014;32:1902–8.

    Article  CAS  PubMed  Google Scholar 

  11. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372:1809–18.

    Article  CAS  PubMed  Google Scholar 

  12. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527–37.

    Article  CAS  PubMed  Google Scholar 

  13. Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013;14(10):953–61.

    Article  CAS  PubMed  Google Scholar 

  14. Mok TS, Wu YL, Yang CH, Chu DT, Saijo N, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.

    Article  CAS  PubMed  Google Scholar 

  15. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.

    Article  CAS  PubMed  Google Scholar 

  16. Sequist LV, Yang JC-H, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR Mutations. J Clin Oncol. 2013;31:3327–34.

    Article  CAS  PubMed  Google Scholar 

  17. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for fi rst-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–22.

    Article  CAS  PubMed  Google Scholar 

  18. Yang JC-H, Shih J-Y, Su W-C, Hsia TC, Tsai CM, Ou SH, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2):a phase 2 trial. Lancet Oncol. 2012;13:539–48.

    Article  CAS  PubMed  Google Scholar 

  19. Zhang Y, Sheng J, Kang S, Fang W, Yan Y, Hu Z, et al. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. PLoS One. 2014;9(9):e107161.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Shao Y-Y, Shau W-Y, Lin Z-Z, Chen HM, Kuo R, Yang JC, et al. Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. Eur J Cancer. 2013;49:106–14.

    Article  CAS  PubMed  Google Scholar 

  21. Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer. 2012;75:82–8.

    Article  PubMed  Google Scholar 

  22. Wu J-Y, Wu S-G, Yang C-H, Chang YL, Chang YC, Hsu YC, et al. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Lung Cancer. 2011;72:205–12.

    Article  PubMed  Google Scholar 

  23. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:3908–14.

    Article  CAS  PubMed  Google Scholar 

  24. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007;11:217–27.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005;97:1185–94.

    Article  CAS  PubMed  Google Scholar 

  26. Cortot AB, Jänne PA. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. Eur Respir Rev. 2014;23(133):356–66.

    Article  PubMed  Google Scholar 

  27. Wang YF, Xiang X, Pei X, Li S, Tang CI, Wang L, et al. Lung adenocarcinoma harboring L858R and T790 M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report. Oncol Lett. 2014;8(3):1039–42.

    PubMed Central  PubMed  Google Scholar 

  28. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790 M mutation. Clin Cancer Res. 2011;17:1616–22.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Department of Radiation Oncology, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Wuhua District, Kunming, 650032, Yunnan Province, China

    Y. Wang, R. Q. Li, J. Zhang & P. Z. Zhao

  2. Cancer Radiotherapy Research Center, The Third Affiliated Hospital, Kunming Medical University, No. 519, Kunzhou Road, Xishan District, Kunming, 650118, Yunnan Province, China

    Y. Q. Ai, Y. F. Li, W. J. He, Y. X. Xia & W. H. Li

Authors
  1. Y. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Q. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Q. Ai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Z. Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y. F. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W. J. He
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y. X. Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W. H. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. H. Li.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Y., Li, R.Q., Ai, Y.Q. et al. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients. Clin Transl Oncol 17, 727–736 (2015). https://doi.org/10.1007/s12094-015-1300-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1300-4

Keywords

Search

Navigation